Use of Dynamic Contrast-Enhanced MRI in Multi-Centre Trials with Particular Reference to Breast Cancer Screening in Women at Genetic Risk

  • Martin O. Leach
Part of the Medical Radiology book series (MEDRAD)


Breast Cancer Magn Reson Image Dynamic Contrast Breast Cancer Susceptibility Gene Breast Cancer Screen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allgayer B, Lukas P, Loos W et al (1993) The MRT of the breast with 2D spin-echo and gradient-echo sequences in diagnostically problematic cases. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 158:423–427PubMedGoogle Scholar
  2. Arias-Mendoza F, Brown TR, Schwarz A et al (2000) Preliminary results of a multi-institutional trial to demonstrate clinical predictive value of in vivo localized 31P MR spectroscopy data in human non-Hodgkin's lynphoma. ISMRM, Berkeley, 1:98. Proceedings of the 8th International Society of Magnetic Resonance in MedicineGoogle Scholar
  3. Aslanian V, Lemaignen H, Bunouf P et al (1995) Clinical evaluation of the tolerability of gadodiamide, a new nonionic contrast agent in MRI of the central nervous system. J Radiol 76:431–434PubMedGoogle Scholar
  4. Aslanian V, Lemaignen H, Bunouf P et al (1996) Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective 11. Neuroradiology 38:537–541CrossRefPubMedGoogle Scholar
  5. Barbier EL, den Boer JA, Peters AR et al (1999) A model of the dual effect of gadopentate dimeglumine on dynamic brain MR images. J Magn Reson Imaging 10:242–253CrossRefPubMedGoogle Scholar
  6. Barkhof F, Filippi M, Miller DH et al (1997) Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials 7. J Neurol 244:76–84CrossRefPubMedGoogle Scholar
  7. Barkhof F, Thompson AJ, Kappos L et al (1993) Database for serial magnetic resonance imaging in multiple sclerosis 13. Neuroradiology 35:362–366CrossRefPubMedGoogle Scholar
  8. Baustert IC, Padhani A, Revell P et al (1998) From qualitative to quantitative measurements of permeability, leakage space and relative blood volume. International Society of Magnetic Resonance in Medicine, Berkeley, Ca 1655, Proceedings of the ISMRM 6th annual meeting, SydneyGoogle Scholar
  9. Brown J, Buckley D, Coulthard A et al (2000a) Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. Magn Reson Imaging 18:765–776CrossRefPubMedGoogle Scholar
  10. Brown J, Coulthard A, Dixon AK et al (2000b) Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast 9:72–77PubMedGoogle Scholar
  11. Brown J, Coulthard A, Dixon AK et al (2000c) Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast 9:78–82CrossRefPubMedGoogle Scholar
  12. D'Arcy JA, Collins DJ, Rowland IJ et al (2002) Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI. NMR Biomed 15:174–183CrossRefPubMedGoogle Scholar
  13. Fischer U, von Heyden D, Vosshenrich R et al (1993) Signal characteristics of malignant and benign lesions in dynamic 2D-MRT of the breast. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 158:287–292PubMedGoogle Scholar
  14. Furman-Haran E, Grobgeld D, Margalit R et al (1998) Response of MCF7 human breast cancer to tamoxifen: evaluation by the three-time-point, contrast-enhanced magnetic resonance imaging method. Clin Cancer Res 4:2299–2304PubMedGoogle Scholar
  15. Greenman RL, Lenkinski RE, Schnall MD (1998) Bilateral imaging using separate interleaved 3D volumes and dynamically switched multiple receive coil arrays. Magn Reson Med 39:108–115PubMedGoogle Scholar
  16. Greenstein Orel S, Schnall MD, Livolsi VA et al (1994) Suspicious breast lesions: MR imaging with radiologic-pathalogic correlation. Radiology 190:485–493PubMedGoogle Scholar
  17. Greenstein Orel S, Schnall MD, Powell CM et al (1995) Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 196:115–122PubMedGoogle Scholar
  18. Harms SE (2001) Integration of breast MRI in clinical trials. J Magn Reson Imaging 13:830–836CrossRefPubMedGoogle Scholar
  19. Harms SE, Flamig DP, Hesley KL et al (1993) MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 187:493–501PubMedGoogle Scholar
  20. Hayes C, Utting J, Leach MO et al (1998) A breast phantom for quality assurance in a multi-centre screening trial. International Society of Magnetic Resonance in Medicine, Berkeley, CA, 2:929. Proceedings of the 6th scientific meeting of the ISMRMGoogle Scholar
  21. Hayes C, Liney G, Leach MO (1999) Quality assurance in the UK multi-centre study of MRI screening for breast cancer. Proceedings of the 7th scientific meeting ISMRM, Philadelphia, vol 2, p 1072. International Society of Magnetic Resonance in Medicine, Berkeley, CA, 2:1072. Proceedings of the 7th scientific meeting ISMRM, PhiladelphiaGoogle Scholar
  22. Hayes C, Padhani AR, Leach MO (2002) Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15:154–163CrossRefPubMedGoogle Scholar
  23. Heywang-Kobrunner SH (1990) Contrast enhanced MRI of the breast. Karger, MunichGoogle Scholar
  24. Heywang-Kobrunner SH, Bick U, Bradley WG Jr et al (2001) International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions. Eur Radiol 11:531–546PubMedGoogle Scholar
  25. Heywang SH, Hahn D, Schmidt H et al (1986) MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 10:199–204PubMedGoogle Scholar
  26. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J et al (1994) Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 31:567–571PubMedGoogle Scholar
  27. Ikeda DM, Hylton NM, Kinkel K et al (2001) Development, standardization, and testing of a lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies. J Magn Reson Imaging 13:889–895CrossRefPubMedGoogle Scholar
  28. International Working Group on Breast MRI (1999) Technical report of the International Working Group on Breast MRI. J Magn Reson Imaging 10:980–981Google Scholar
  29. Julian TB (2001) MRI: a role in clinical trials. J Magn Reson Imaging 13:837–841CrossRefPubMedGoogle Scholar
  30. Kaiser WA, Zeitler E (1989) MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 170:681–686PubMedGoogle Scholar
  31. Knopp MV, Brix G, Junkermann HJ et al (1994) MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin North Am 2:633–658Google Scholar
  32. Kuhl CK (2003) High-risk screening: multi-modality surveillance of women at high risk of breast cancer (proven or suspected carriers of a breast cancer susceptibility gene). J Exp Clin Cancer Res 21:103–106Google Scholar
  33. Kuhl CK, Bieling H, Gieseke J et al (1997) Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging. Radiology 202:87–95PubMedGoogle Scholar
  34. Kuhl CK, Mielcareck P, Klaschik S et al (1999) Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211:101–110PubMedGoogle Scholar
  35. Kuhl CK, Schmutzler RK, Leutner CC et al (2000) Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215:267–279PubMedGoogle Scholar
  36. Kvistad KA, Lundgren S, Fjosne H et al (1999) Differentiating benign and malignant breast lesions with T2*-weighted first pass perfusion imaging. Acta Radiol 40:45–51PubMedGoogle Scholar
  37. Leach MO and MARIBS Advisory Group Study Advisory Committe (2002) The UK national study study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). J Exp Clin Cancer Res 21:107–114Google Scholar
  38. Leach MO (1997) Protocol 97PRT/4: National study of magnetic resonance imaging to screen women at genetic risk of breast cancer. Lancet, isa?n1=authorinfo&n2=Protocol+review&uid=1187Google Scholar
  39. Leach MO (2001) Application of magnetic resonance imaging to angiogenesis in breast cancer. Breast Cancer Res 3:22–27CrossRefPubMedGoogle Scholar
  40. Leach MO (2002) Assessing response to treatment in breast cancer using magnetic resonance. J Exp Clin Cancer Res 21:111Google Scholar
  41. Leach MO, Kessar P (2002) Breast MRI and screening. In: Warren R, Coulthard A (eds) Breast MRI in practice. Dunitz, London, pp 227–236Google Scholar
  42. Leach MO, Arnold D, Brown TR et al (1994) International workshop on standardization in clinical magnetic resonance spectroscopy measurements: proceedings and recommendations. Acad Radiol 1:171–186PubMedGoogle Scholar
  43. Li KL, Zhu XP, Waterton J et al (2000) Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumours. J Magn Reson Imaging 12:347–357CrossRefPubMedGoogle Scholar
  44. Miller AB, Hoogstraten B, Staquet M (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedGoogle Scholar
  45. Moss S, Chamberlain J (1996) Screening for cancer of the breast. In: Chamberlain J, Moss S (eds) Evaluation of cancer screening. Springer, Berlin Heidelberg New York, pp 33–53Google Scholar
  46. National Institutes of Health Consensus Statement (1997) Breast cancer screening for women aged 40–49, 21–23 Jan 1997. National Cancer Institute, Bethesda MDGoogle Scholar
  47. Negendank W, Sauter R (1996) Intratumoral lipids in 1H MRS in vivo in brain tumors: experience of the Siemens cooperative clinical trial. Anticancer Res 16:1533–1538PubMedGoogle Scholar
  48. Negendank WG, Sauter R, Brown TR et al (1996) Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 84:449–458PubMedGoogle Scholar
  49. Nyland H, Myhr KM, Lillas F et al (1996) Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway. Mult Scler 1:372–375PubMedGoogle Scholar
  50. Orel SG (2000) MR imaging of the breast. Radiol Clin North Am 38:899–913CrossRefPubMedGoogle Scholar
  51. Orel SG, Schnall MD (1999) High risk screening working group report. J Magn Reson Imaging 10:995–1005PubMedGoogle Scholar
  52. Ostergaard L, Sorenson AG, Kwong KK et al (1996) High resolution measurement of cerebral blood flow using extravascular tracer bolus passages, part II. Experimental comparison and preliminary results. Magn Reson Med 36:726–736PubMedGoogle Scholar
  53. Paley M, Cozzone PJ, Alonso J et al (1996) A multicenter proton magnetic resonance spectroscopy study of neurological complications of AIDS. AIDS Res Hum Retroviruses 12:213–222PubMedGoogle Scholar
  54. Parker GJ, Suckling J, Tanner SF et al (1997) Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 7:564–574PubMedGoogle Scholar
  55. Parker GJ, Suckling J, Tanner SF et al (1998) MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer. Radiographics 18:497–506PubMedGoogle Scholar
  56. Parodi RC, Sardanelli F, Renzetti P et al (2002) Growing Region Segmentation Software (GRES) for quantitative magnetic resonance imaging of multiple sclerosis: intra-and interobserver agreement variability: a comparison with manual contouring method. Eur Radiol 12:866–871CrossRefPubMedGoogle Scholar
  57. Podo F, Sardanelli F, Canese R et al (2002) The Italian multicentre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 21:115–124Google Scholar
  58. Saini S, Sharma R, Baron RL et al (2000) Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. Clin Radiol 55:690–695PubMedGoogle Scholar
  59. Sijens PE, Knopp MV, Brunetti A et al (1995) 1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study. Magn Reson Med 33:818–826PubMedGoogle Scholar
  60. Tesoro-Tess JD, Amoruso A et al (1995) Microcalcifications in clinically normal breast — the value of high field, surface coil, Gd-DTPA-enhanced MRI. Eur Radiol 5:417–422CrossRefGoogle Scholar
  61. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedGoogle Scholar
  62. Tofts P, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental Concepts. Magn Reson Med 17:357–367PubMedGoogle Scholar
  63. Tofts PS, Berkowitz B, Schnall MD (1995) Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 33:564–568PubMedGoogle Scholar
  64. Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMedGoogle Scholar
  65. Vonken EPA, van Osch MJP, Bakkar CJG et al (2003) Simultaneous quantitative cerebral perfusion and Gd-DTPA extravasation measurement with dual-echo dynamic susceptibility contrast MRI. Magn Reson Med 43:820–827CrossRefGoogle Scholar
  66. Wang C, Ahlstrom H, Ekholm S et al (1997) Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study 6. Acta Radiol 38:643–649PubMedGoogle Scholar
  67. Weinstein D, Strano S, Cohen P et al (1999) Breast fibroadenoma: mapping of pathophysiologic features with three-time-point, contrast-enhanced MR imaging—pilot study. Radiology 210:233–240PubMedGoogle Scholar
  68. Zhu XP, Li KL, Kamaly-Asl ID et al (2000) Quantification of endothelial permeability, leakage space and blood volume in brain tumours using combined T1 and T2* contrast-enhanced dynamic MR. J Magn Reson Imaging 11:575–585CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Martin O. Leach
    • 1
  1. 1.Cancer Research UK, Clinical Magnetic Resonance Research GroupInstitute of Cancer Research and Royal Marsden HospitalSutton, SurreyUK

Personalised recommendations